Healthcare -
Drug Manufacturers - General - NASDAQ - FR
$ 51.675
0.0589 %
$ 130 B
Market Cap
20.54
P/E
1. INTRINSIC VALUE
Balance Sheet
Sanofi
| Current Assets | 42.6 B |
| Cash & Short-Term Investments | 7.93 B |
| Receivables | 10.6 B |
| Other Current Assets | 24 B |
| Non-Current Assets | 90.2 B |
| Long-Term Investments | 3.26 B |
| PP&E | 11.6 B |
| Other Non-Current Assets | 75.4 B |
| Current Liabilities | 29.2 B |
| Accounts Payable | 7.55 B |
| Short-Term Debt | 4.47 B |
| Other Current Liabilities | 17.1 B |
| Non-Current Liabilities | 25.8 B |
| Long-Term Debt | 13.4 B |
| Other Non-Current Liabilities | 12.3 B |
EFFICIENCY
Earnings Waterfall
Sanofi
| Revenue | 44.3 B |
| Cost Of Revenue | 13.2 B |
| Gross Profit | 31.1 B |
| Operating Expenses | 23.8 B |
| Operating Income | 7.25 B |
| Other Expenses | 1.76 B |
| Net Income | 5.5 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sanofi
| Net Income | 5.5 B |
| Depreciation & Amortization | 3.59 B |
| Capital Expenditures | -3.2 B |
| Stock-Based Compensation | 0 |
| Change in Working Capital | -615 M |
| Others | 517 M |
| Free Cash Flow | 5.89 B |
Wall Street Analysts Price Targets
Sanofi
Wall Street analysts predict an average 1-year price target for SNY of $58.5 , with forecasts ranging from
a
low of
$48.1 to a high of $64 .
SNY Lowest Price Target
Wall Street Target
48.1 USD
-6.98%
SNY Average Price Target
Wall Street Target
58.5 USD
13.23%
SNY Highest Price Target
Wall Street Target
64 USD
23.85%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
1.61 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Sanofi
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
zacks.com
- 1 week ago
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.
zacks.com
- 1 week ago
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
reuters.com
- 2 weeks ago
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved Paris and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.
globenewswire.com
- 2 weeks ago
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
zacks.com
- 2 weeks ago
Press Release: Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in addition to asthma Itepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis; phase 3 readouts in COPD in H2 2025 and bronchiectasis in 2026 Paris, April 15, 2025. Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.
globenewswire.com
- 2 weeks ago
Why You Shouldn't Bet Against Sanofi (SNY) Stock
Sanofi (SNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
zacks.com
- 3 weeks ago
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MS Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026 Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved.
globenewswire.com
- 3 weeks ago
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
zacks.com
- 4 weeks ago
Why Is French Pharma Giant Sanofi Stock Trading Higher On Thursday?
The U.S. Food and Drug Administration (FDA) on Thursday granted orphan drug designation to Sanofi SA‘s SNY rilzabrutinib.
benzinga.com
- 4 weeks ago
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for two rare diseases, warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD).
globenewswire.com
- 4 weeks ago
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix to date to $105 million Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones for this program as well as potential future royalties and retains an option to co-develop and co-promote in the United States with the parties splitting U.S. profits and losses SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today that Sanofi has exclusively licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases. The undisclosed target is a central regulator of the inflammation response and is distinct from the previously disclosed STAT6 degrader program.
globenewswire.com
- 1 month ago
8. Profile
Summary
Sanofi SNY
COUNTRY
FR
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 130 B
Dividend Yield
0.00%
Description
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Contact
54, Rue La BoEtie, Paris, 75008
https://www.sanofi.com
IPO
Date
July 1, 2002
Employees
82878
Officers
Mr. Paul Hudson
Chief Executive Officer & Director
Mr. François-Xavier Roger
Executive Vice President & Chief Financial Officer
Ms. Madeleine Roach
Executive Vice President & Head of Business Operations
Dr. Josephine Fubara
Chief Science Officer of Consumer Health Care
Mr. Pierre Chancel
Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Mr. Roy Papatheodorou
Executive Vice President & General Counsel
Mr. Laurent Gilhodes
Principal Accounting Officer and Vice President of Corporate Accounting
Mr. Thomas Kudsk Larsen
Head of Investor Relations
Mr. Josep Catlla
Head of Communications
Mr. Dante Beccaria
Global Compliance Officer & Vice President